Gemcitabine is a widely used chemotherapy drug that acts by targeting DNA replication. Understanding why many tumors are unresponsive to gemcitabine is a clinical challenge. A new study in Nature Cancer reports that upregulation of the cytidine deaminases APOBEC3C and APOBEC3D facilitates resistance to gemcitabine by protecting cells against DNA replication stress.
This is a preview of subscription content, log in via an institution to check access.
References
Hertel, L. W. et al. Cancer Res. 50, 4417–4422 (1990).
Ubhi, T. et al. Nat. Cancer https://doi.org/10.1038/s43018-024-00742-z (2024).
Petljak, M. et al. Nature 607, 799–807 (2022).
Isozaki, H. et al. Nature 620, 393–401 (2023).
Durfee, C. et al. Cell Rep. Med. 4, 101211 (2023).
Petljak, M. et al. Cell 176, 1282–1294.e20 (2019).
Caswell, D. R. et al. Nat. Genet. 56, 60–73 (2024).
Wörmann, S. M. et al. Nat. Can. 2, 1338–1356 (2021).
Mehta, K. P. M., Lovejoy, C. A., Zhao, R., Heintzman, D. R. & Cortez, D. Cell Rep. 31, 107705 (2020).
Thompson, P. S. & Cortez, D. DNA Repair (Amst.) 90, 102866 (2020).
Petljak, M., Green, A. M., Maciejowski, J. & Weitzman, M. D. Nat. Genet. https://doi.org/10.1038/s41588-022-01196-8 (2022).
Kawale, A. S. et al. Sci. Adv. 10, eadk2771 (2024).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Maciejowski, J., Mohamed, T. APOBEC3 upregulation drives gemcitabine resistance. Nat Cancer 5, 818–820 (2024). https://doi.org/10.1038/s43018-024-00755-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-024-00755-8
- Springer Nature America, Inc.